Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients

Yoshiyuki Morishita
Minami Watanabe
Shiho Hanawa
Osamu Iimura
Sadao Tsunematsu
Kenichi Ishibashi
Eiji Kusano

Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan; Kumakura Clinic, Tochigi, Japan; Yuki Clinic, Ibaragi, Japan; Department of Medical Physiology, Meiji Pharmaceutical University, Tokyo, Japan

Objective: The long-term effects of aliskiren in hypertensive hemodialysis patients remain to be elucidated.

Design: In this post hoc analysis, we followed up 25 hypertensive hemodialysis patients who completed 8-week aliskiren treatment in a previous study for 20 months to investigate the blood pressure-lowering effect and inhibitory effect on the renin-angiotensin-aldosterone system.

Results: Among the 25 patients, eleven patients continued with aliskiren treatment. Blood pressure (± standard deviation) decreased from 175 ± 18/80 ± 11 mmHg at baseline to 156 ± 20/76 ± 9 mmHg at month 20. Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05)).

Conclusion: Long-term treatment with aliskiren provides effective blood pressure lowering and inhibition of the renin-angiotensin-aldosterone system, which are sustained over 20 months in hypertensive hemodialysis patients.

Keywords: aliskiren, blood pressure, renin, angiotensin, aldosterone, hemodialysis patients, long-term effects

Introduction

Hypertension and cardiovascular disease (CVD) are common in hemodialysis (HD) patients. Recent meta-analyses demonstrated that antihypertensive pharmacotherapy reduced CVD in HD patients. The renin-angiotensin-aldosterone system (RAAS) contributes to hypertension and CVD in hypertensive HD patients. Previous studies suggested that RAAS blockers such as angiotensin I converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were effective for blood pressure (BP) control and CVD protection in hypertensive HD patients.

In a previous study, we reported that an oral direct renin inhibitor, aliskiren, was effective for BP control and could have CVD protective effects in hypertensive HD patients in 8-week treatment periods; however, its long-term effects in hypertensive HD patients remain to be elucidated. In this post hoc analysis, we followed up the hypertensive HD patients who completed the previous study for 20 months to investigate the BP-lowering effect and inhibitory effects on RAAS and surrogate markers of CVD, such as brain natriuretic peptide (BNP) and an oxidative stress marker, diacron-reactive oxygen metabolites (d-ROM), of aliskiren in hypertensive HD patients.
Methods
This study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of Jichi Medical University. Written informed consent was obtained from all patients.

Patients and study protocol
Details of the protocol of aliskiren for hypertensive HD patients in the 8-week trials in the previous study have been published previously. Briefly, the study was a multicenter clinical trial of 30 hypertensive HD patients. Subjects were enrolled between January 2010 and February 2010 and assigned aliskiren at 150 mg orally in the morning once daily with their existing antihypertensives. The end point of the previous study was to determine the changes of RAAS, BP, and surrogate markers of CVD after 8 weeks of aliskiren treatment. After the end of the previous study, the continuation of aliskiren treatment was determined by physicians on basis of the patients’ BP levels. As shown in Figure 1, in this post hoc analysis, we followed up the hypertensive HD patients who completed the previous study for 20 months to investigate the changes of BP, RAAS, and surrogate markers of CVD in both hypertensive HD patients who continued with aliskiren treatment (aliskiren group) and those who were withdrawn from aliskiren treatment (aliskiren-withdrawal group).

Monitoring BP, RAAS, and CVD surrogate markers
Systolic BP (SBP) and diastolic BP (DBP) were measured before all HD sessions. The reported monthly SBP and DBP were the average of each SBP and DBP on the last HD day of the week. Blood samples were obtained from arteriovenous shunt before HD sessions. Plasma renin activity (PRA), angiotensin I (AT I), angiotensin II (AT II), aldosterone (Ald), BNP, and d-ROM levels were compared at baseline and at months 2 and 20. Standard laboratory tests were performed in the observation period in each month in the treatment period.

Laboratory methods
PRA, Ald, and BNP levels were determined by the radioimmunoassay method. AT I and AT II levels were measured by a double antibody radioimmunoassay method; the details of these methods have been described elsewhere. PRA, AT I, AT II, BNP, and other blood chemistry levels were determined by a clinical chemistry laboratory (SRL, Inc, Tokyo, Japan). d-ROM values were measured using the Free

---

**Figure 1** Patient flow chart.
Radical Analysis System 4 (Wismerll, Tokyo, Japan); the details of this method have been described elsewhere.\textsuperscript{17,18}

**Statistical analysis**
All data are expressed as the mean ± standard deviation. Baseline characteristics were compared between groups with unpaired $t$-test. The parameters within each group were compared with paired $t$-test. Differences with a $P$-value $< 0.05$ were considered significant.

**Results**
In a previous study, 25 of 30 hypertensive HD patients completed an 8-week aliskiren treatment trial. Twenty-three of the 25 patients had been taking antihypertensive drugs before aliskiren treatment, including calcium antagonists (16 patients), ACEIs (six patients), ARBs (18 patients), $\beta$-blockers (four patients), $\alpha$-blockers (seven patients), $\alpha\beta$-blockers (four patients), and $\alpha$-methyldopa (five patients). Among these 25 patients, 11 patients continued aliskiren treatment with their pre-existing antihypertensives including calcium antagonists (four patients), ARBs (seven patients), $\beta$-blockers (two patients), and $\alpha$-blockers (three patients) during this study period (aliskiren group). Ten patients were withdrawn from aliskiren treatment from month 3 to month 8 (month 3, one patient; month 4, three patients; month 6, two patients; month 7, two patients; and month 8, two patients) owing to symptomatic hypotension. These ten patients had their BP controlled by antihypertensives other than aliskiren including calcium antagonists (eight patients), ACEIs (three patients), ARBs (eight patients), $\beta$-blockers (two patients), $\alpha$-blockers (three patients), $\alpha\beta$-blockers (four patients), and $\alpha$-methyldopa (three patients) during this study period (aliskiren-withdrawal group). Two patients died of heart failure under aliskiren treatment (one patient) and after withdrawal from aliskiren treatment (one patient) and one patient died of pneumonia under aliskiren treatment. One patient was transferred to hospital. These four patients were excluded from analysis. Table 1 shows the characteristics of the study patients in both the aliskiren group and the aliskiren-withdrawal group at baseline. There were no statistical differences in age, body mass index, time on dialysis, average time of a dialysis, average ultrafiltration, and duration of hemodialysis between the aliskiren group and the aliskiren-withdrawal group.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Aliskiren group</th>
<th>Aliskiren-withdrawal group</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>11</td>
<td>10</td>
<td>0.56</td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.3 ± 7.4</td>
<td>67.2 ± 8.1</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>23.2 ± 3.0</td>
<td>23.8 ± 3.1</td>
<td>0.42</td>
</tr>
<tr>
<td>Time on dialysis (weeks)</td>
<td>2.9 ± 0.2</td>
<td>2.8 ± 0.2</td>
<td>0.51</td>
</tr>
<tr>
<td>Average time of the dialysis (hours)</td>
<td>4.0 ± 0.2</td>
<td>4.0 ± 0.3</td>
<td>0.63</td>
</tr>
<tr>
<td>Average ultrafiltration (kg/hours/HD section)</td>
<td>2.8 ± 1.1</td>
<td>2.7 ± 1.4</td>
<td>0.81</td>
</tr>
<tr>
<td>Duration of hemodialysis (years)</td>
<td>6.9 ± 7.2</td>
<td>6.8 ± 6.2</td>
<td>0.76</td>
</tr>
<tr>
<td>Initial nephropathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic glomerulonephritis</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>7</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>ANCA-associated glomerulonephritis</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Drug nephropathy</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Malignant hypertension</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>175.0 ± 18.0</td>
<td>171.0 ± 13.0</td>
<td>0.30</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>80.0 ± 11.0</td>
<td>80.0 ± 14.0</td>
<td>0.89</td>
</tr>
<tr>
<td>HR (beats/minute)</td>
<td>78.0 ± 12.0</td>
<td>76.0 ± 10.0</td>
<td>0.91</td>
</tr>
<tr>
<td>PRA (ng/mL/hr)</td>
<td>2.3 ± 2.6</td>
<td>3.3 ± 2.9</td>
<td>0.41</td>
</tr>
<tr>
<td>ATI (pg/mL)</td>
<td>909.1 ± 902.5</td>
<td>999.1 ± 844.6</td>
<td>0.82</td>
</tr>
<tr>
<td>ATII (pg/mL)</td>
<td>41.5 ± 45.8</td>
<td>30.6 ± 36.7</td>
<td>0.56</td>
</tr>
<tr>
<td>Ald (pg/mL)</td>
<td>163.5 ± 214.3</td>
<td>97.2 ± 57.5</td>
<td>0.58</td>
</tr>
<tr>
<td>BNP (pg/mL)</td>
<td>248.9 ± 197.2</td>
<td>425.3 ± 207.3</td>
<td>0.06</td>
</tr>
<tr>
<td>d-ROM (U.CARR)</td>
<td>386.6 ± 123.1</td>
<td>402.3 ± 69.0</td>
<td>0.72</td>
</tr>
</tbody>
</table>

**Abbreviations**: BMI, body mass index; HD, hemodialysis; ANCA, SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PRA, plasma renin activity; ATI, angiotensin I; ATII, angiotensin II; Ald, aldosterone; BNP, brain natriuretic peptide; d-ROM, diacron-reactive oxygen metabolite; U.CARR, Carratelli units.
and the aliskiren-withdrawal group at baseline (Table 1) and at month 2 (data not shown). Increased serum potassium was not observed in any patients in both the aliskiren group and the aliskiren-withdrawal group throughout the treatment period.

Effect of aliskiren on BP

Figure 2 shows the changes of SBP and DBP in the aliskiren group and the aliskiren-withdrawal group. There was no statistical difference in SBP and DBP between the aliskiren group and the aliskiren-withdrawal group at baseline (Table 1 and Figure 2) and at month 2 (Figure 2). There was also no difference in hypotension episodes during HD between the aliskiren group and the aliskiren-withdrawal group during the study period. SBP and DBP (± standard deviation) decreased from 175 ± 18/80 ± 11 mmHg at baseline to 156 ± 20/76 ± 9 mmHg at month 2 and 155 ± 19/76 ± 9 mmHg at month 20 in the aliskiren group. The SBP and DBP of patients who received ARBs and those who did not receive ARBs did not show a difference in the aliskiren group during the study period. SBP and DBP (± standard deviation) also decreased from 171 ± 13/80 ± 14 mmHg at baseline to 159 ± 17/79 ± 12 mmHg at month 2 and 157 ± 26/77 ± 12 mmHg at month 20 in the aliskiren-withdrawal group. Although a trend of lower SBP was detected in the aliskiren-withdrawal group between month 4 and month 7, SBP and DBP did not show a statistical difference between the aliskiren group and the aliskiren-withdrawal group throughout the follow-up period.

Blockade of RAAS by aliskiren

Each factor of RAAS at baseline in both the aliskiren group and the aliskiren-withdrawal group is shown in Table 1. There were no statistically significant differences in each factor of RAAS between the aliskiren group and the aliskiren-withdrawal group at baseline (Table 1 and Figure 3) and at month 2 (Figure 3). In the aliskiren group, PRA, AT I, AT II, and Ald decreased from baseline to month 2, and this decreased level continued at month 20 (PRA (ng/mL/h): 2.3 ± 2.6 (baseline) – 0.5 ± 0.5 (month 2) (P < 0.05) – 0.3 ± 0.4 (month 20) (P < 0.05), AT I (pg/mL): 909.1 ± 902.5 (baseline) – 271.7 ± 166.0 (month 2) (P < 0.05) – 41.5 ± 14.8 (month 20) (P < 0.05), AT II (pg/mL): 41.5 ± 45.8 (baseline) – 10.0 ± 9.9 (month 2) (P < 0.05) – 11.0 ± 9.9 (month 20) (P < 0.05), Ald (pg/mL): 163.5 ± 214.3 (baseline) – 74.2 ± 33.2 (month 2) (P = 0.29) – 63.4 ± 20.0 (month 20) (P = 0.09)) (Figure 2). On the other hand, in the aliskiren-withdrawal group, although PRA, AT I, AT II, and Ald decreased at month 2 with aliskiren treatment (PRA (ng/mL/h): 3.3 ± 2.9 (baseline) – 0.9 ± 0.7 (month 2) (P < 0.05), AT I (pg/mL): 999.1 ± 844.6 (baseline) – 365.6 ± 211.6 (month 2) (P < 0.05), AT II (pg/mL): 30.6 ± 36.7 (baseline) – 8.4 ± 10.7 (month 2) (P < 0.05), Ald (pg/mL): 97.2 ± 57.5 (baseline) – 79.3 ± 35.7 (month 2) (P = 0.25)), they increased to the level of baseline upon withdrawal.
of aliskiren at month 20 (PRA (ng/mL/h): 4.1 ± 3.3 (P = 0.37), AT I (pg/mL): 801.0 ± 1032.8 (P = 0.30), AT II (pg/mL): 26.1 ± 17.2 (P = 0.58), Ald (pg/mL): 108.8 ± 106.7 (P = 0.78)) (Figure 3).

Inhibition of BNP and d-ROM by aliskiren
Although there were no statistically significant differences in BNP and d-ROM level between the aliskiren group and the aliskiren-withdrawal group at baseline and at month 2, BNP showed a tendency to be higher in the aliskiren-withdrawal group (Table 1). In the aliskiren group, although there was no statistical significance, BNP and d-ROM tended to decrease from baseline to month 2 followed by a further decrease at month 20 (BNP (pg/mL): 248.9 ± 197.2 (baseline) – 232.8 ± 133.1 (P = 0.71) (month 2) – 203.7 ± 113.3 (P = 0.53) (month 20), d-ROM (Carratelli Units [U.CARR]): 386.6 ± 123.1 (baseline) – 356.3 ± 120.5 (P = 0.16) (month 2) – 305.6 ± 67.4 (P = 0.08) (month 20)) (Figure 4). On the other hand, in the aliskiren-withdrawal group, BNP initially showed a tendency to decrease from baseline to month 2; however, it did not decrease from month 2 to month 20 (BNP (pg/mL): 425.3 ± 207 (baseline) – 409.5 ± 287.8 (P = 0.82) (month 2) – 412.9 ± 287.8 (P = 0.88) (month 20)) (Figure 4). d-ROM tended to decrease from baseline to month 2 followed by a further decrease at month 20 (d-ROM (U.CARR): 402.3 ± 69.0 (baseline) – 362.3 ± 47.8 (P = 0.09) (month 2) – 336.3 ± 58.5 (P = 0.07) (month 20)) (Figure 4).

Discussion
The results of this study show that aliskiren significantly decreased SBP and DBP as well as inhibited RAAS for the long term in hypertensive HD patients. The aliskiren-withdrawal patients showed re-upregulation of RAAS although their SBP and DBP were controlled at levels similar to those of the aliskiren group by antihypertensives, except for RAAS blockers. These results suggest that aliskiren significantly inhibited RAAS and had BP-lowering effects in hypertensive HD patients for the long-term. In addition, although statistical significance was not reached, which was considered to be
due to the small number of samples, BNP (pg/mL) decreased from baseline (248.9 ± 197.2) to month 2 (232.8 ± 133.1) followed by a further decrease at month 20 (203.7 ± 113.3) in the aliskiren group. On the other hand, in the aliskiren-withdrawal group, although BNP (pg/mL) decreased from baseline (425.3 ± 207.3) to month 2 (409.5 ± 287.8 pg/mL) with aliskiren treatment, it did not decrease from month 2 to month 20 (412.9 ± 287.8 pg/mL) by withdrawal of aliskiren under similar levels of SBP and DBP as those of the aliskiren group. BNP reduction has consistently been associated with an improved outcome in heart failure.19–21 For instance, an increment of 10 pg/mL in BNP was associated with a 1.2% increased risk of death.19 Although we did not perform echocardiography to monitor the change of cardiac functions by aliskiren treatment during this period, these results suggested that both the aliskiren group and the aliskiren-withdrawal group may not exhibit worse cardiac functions. In addition, aliskiren might have cardioprotective effects in hypertensive HD patients. Side effects of aliskiren including hyperpotassemia were not detected in any patients throughout the follow-up period in both the aliskiren group and the aliskiren-withdrawal group. We previously reported that aliskiren was effective for BP control and inhibition of RAAS in hypertensive HD patients in the short-term, namely, by 8 weeks of analysis.14 Since the rate of discontinuation of aliskiren treatment (150 mg/day) owing to symptomatic hypotension was high (eleven of 25 patients) in this study, it may be better to reduce the initial dose of aliskiren to less than 150 mg/day, and careful observation for BP change is required for aliskiren treatment in hypertensive HD patients. Further studies including kinetic analysis of aliskiren will need to investigate the optimal dose of aliskiren in hypertensive HD patients. Taken together, the results of this study suggest that aliskiren is effective for BP control and inhibition of RAAS, which may lead to cardiovascular protective effects in hypertensive HD patients in the long term, although they need careful monitoring of BP change.

Disclosure
All authors report no conflicts of interest in this work.

References


